Glaucoma, Ocular Hypertension
Conditions
Keywords
Glaucoma and Ocular Hypertension
Brief summary
Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months. These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).
Interventions
None listed
Sponsors
Cairo University
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 72 Years
Inclusion criteria
* Glaucoma and Ocular Hypertension
Exclusion criteria
* Any ocular disease or medication that may raise the intraocular pressure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of intraocular pressure lowering of bimatoprost versus travoprost. | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of development of complications. | — |
Countries
Egypt
Outcome results
None listed